George Clinical is pleased to confirm the appointment of Mary Gunn as its new Chief Executive Officer. As a global executive, Mary brings to the role extensive experience in high-growth life sciences, financial services, and the education sectors. Mary will also be a director on the Board. Mary Gunn succeeds James Cheong who has served […]
Read MoreRace Oncology Limited recently announce the appointment of George Clinical to support the oncology clinical development of RC220 bisantrene. George Clinical was selected after an extensive and rigorous selection process conducted by the Race Oncology clinical team. In addition to clinical trial expertise, George Clinical, brings access to a supplementary network of key opinion leading […]
Read MoreRace Oncology Limited recently announce the appointment of George Clinical to support the oncology clinical development of RC220 bisantrene. George Clinical was selected after an extensive and rigorous selection process conducted by the Race Oncology clinical team. In addition to clinical trial expertise, George Clinical, brings access to a supplementary network of key opinion leading […]
Read MoreOmico Will Precisely Match Patients to George Clinical Oncology Trials SYDNEY, July 28, 2023 – George Clinical recognises and applauds its collaborative partner Omico, with whom it is aligned in a common goal to revolutionize oncology clinical trial access for patients and improve the efficiency of study enrollment, on the launch of their landmark program […]
Read MoreMedidata, a Dassault Systèmes company, recently announced George Clinical is implementing Medidata’s cloud-based clinical solutions – Rave Grants Manager – to improve tracking and management of budgets. Medidata’s solution will also empower George Clinical to bring operational efficiency and improve patient recruitment by sites. The implementation will give George Clinical’s global clients the usage of […]
Read MoreSYDNEY, June 27, 2023 – George Clinical and EPS Corporation (EPS), a global CRO based in Japan are collaborating on a rare Japanese academia-led global study seeking to advance treatments for unmet needs in Asian populations. In 2019 George Clinical and EPS formed a strategic partnership to help expand their operations across the Asia-Pacific region. […]
Read MoreGeorge Clinical recently received the award for Clinical Research Team of the Year at the 7th Annual Citeline Awards held in Boston, MA. As a 2023 winner, the George Clinical team won recognition for a multi-site program in the Asia Pacific region that recruited more than 3,000 patients across 14 sites in just seven weeks. […]
Read MoreFrost & Sullivan studied the contract research organization industry and, based on its findings, recognizes George Clinical with the 2023 Asia-Pacific Competitive Strategy Leadership Award. George Clinical is a global CRO with world class expertise in kidney research, oncology and neurology and remains fully committed to growing their strong presence in Asia-Pacific which is where the company has […]
Read MoreSYDNEY, May 4, 2023 – George Clinical announces that the company has initiated preparations in Australia for two oncology Phase 1b trials that will examine a Hummingbird Bioscience precision therapy program targeting HER3, a potent driver of tumor growth and resistance against cancer drugs, in biomarker-selected patient populations, including lung cancer. George Clinical is providing […]
Read MoreThe 4th Annual Chronic Kidney Disease Drug Development (CKD3) Summit saw a select group of scientists, clinical researchers and experts from industry and regulatory agencies gathered face-to-face for the first time since the pandemic. Excitement and enthusiasm were evident as these experts networked and collaborated on how the latest scientific research is being applied to […]
Read More
